MRSA treatment 'may be more effective' if alternative drug used
The drug linezolid (Zyvox) may be more effective at treating patients with MRSA nosocomial pneumonia than the current gold standard vancomycin, according to trial results published in the journal Clinical Infectious Diseases.
Patients were randomized to receive intravenous linezolid (600 mg every 12 hours) or vancomycin (15 mg/kg every 12 hours) for up to two weeks.
Results showed 57.6% of 165 linezolid patients were cured, compared with 46.6% of 174 vancomycin patients.
However, there was no difference in mortality rates after 60 days and incidence of adverse events.